- Joubert syndrome is a rare genetic disorder affecting the cerebellum and brainstem, leading to developmental delays, hypotonia, and breathing abnormalities. Current treatment focuses on symptom relief, physiotherapy, respiratory support, and investigational gene therapies
- The market is supported by improving access to pediatric neurology services, increased genetic counseling, and a growing pipeline of experimental treatments
- North America dominates the Joubert Syndrome Treatment market with a share of approximately 41.6%, driven by active rare disease registries, early diagnostic initiatives, and presence of specialized care centers
- Asia-Pacific is projected to register the highest CAGR during the forecast period due to increasing government initiatives in rare disease management and improvements in neonatal screening
- The physical therapy segment is expected to account for the highest growth rate and largest market share of 42.28%, driven by its essential role in enhancing neuromotor development and managing hypotonia, a core symptom of joubert syndrome
